Quick Navigation
Topics
Quantum State Preparation Representation
OP42 Cost-Utility Analysis Of Axicabtagene Ciloleucel (Yescarta) Versus Standard Care For Relapsed Or Refractory Large B-Cell Lymphoma – Health Payer Perspective
Europe PMC
Authors: Unknown
Year
2025
Paper ID
1130
Status
Peer-reviewed
Abstract Read
~2 min
Abstract Words
0
Citations
N/A
Abstract
No abstract available.
Why This Paper Matters
- This paper contributes to the Quantum State Preparation & Representation research area in the Quantum Articles archive.
- It adds a 2025 reference point for readers tracking recent quantum research.
Paper Tools
Become a member to use research tools
Sign in to open papers, visit source links, share, cite, compare, copy DOI links, request category corrections, and build your reading list.
Publisher Share
Cite This Paper
Copy URL
Compare
Copy DOI Add to Reading List
Category Correction Request
Category Correction Request
Help us improve classification quality by proposing a better category. Every request is reviewed by an admin.
Sign in to submit a category correction request for this paper.
Log In to SubmitReferences & Citation Signals
Community Reactions
Quick sentiment from readers on this paper.
Score:
0
Likes: 0
Dislikes: 0
Sign in to react to this paper.
Discussion & Reviews (Moderated)
Average Rating: 0.0 / 5 (0 ratings)
No written reviews yet.